Q4 2022 13F Holders as of 12/31/2022
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
76.6M
-
Number of holders
-
118
-
Total 13F shares, excl. options
-
42.7M
-
Shares change
-
+357K
-
Total reported value, excl. options
-
$469M
-
Value change
-
+$2.14M
-
Put/Call ratio
-
0
-
Number of buys
-
63
-
Number of sells
-
-45
-
Price
-
$10.98
Significant Holders of Nurix Therapeutics, Inc. - Common Stock (NRIX) as of Q4 2022
133 filings reported holding NRIX - Nurix Therapeutics, Inc. - Common Stock as of Q4 2022.
Nurix Therapeutics, Inc. - Common Stock (NRIX) has 118 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 42.7M shares
of 76.6M outstanding shares and own 55.69% of the company stock.
Largest 10 shareholders include BlackRock Inc. (4.14M shares), BAKER BROS. ADVISORS LP (3.88M shares), PRICE T ROWE ASSOCIATES INC /MD/ (3.25M shares), Redmile Group, LLC (3M shares), WASATCH ADVISORS INC (2.54M shares), STATE STREET CORP (2.51M shares), Deep Track Capital, LP (2.27M shares), VANGUARD GROUP INC (2.2M shares), ARK Investment Management LLC (1.99M shares), and Bain Capital Life Sciences Investors, LLC (1.82M shares).
This table shows the top 118 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.